Dimerization inhibitors of HIV-1 protease.

Insight into the self-association of key enzymes from pathogenic species. Eur Biophys J (2005) 1.09

Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. Drug Discov Today (2010) 0.96

Biochemical and structural characterization of alanine racemase from Bacillus anthracis (Ames). BMC Struct Biol (2009) 0.95

Structural features and kinetic characterization of alanine racemase from Staphylococcus aureus (Mu50). Acta Crystallogr D Biol Crystallogr (2011) 0.94

The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design. BMC Microbiol (2011) 0.91

Analysis and characterization of dimerization inhibition of a multi-drug-resistant human immunodeficiency virus type 1 protease using a novel size-exclusion chromatographic approach. Biochem J (2009) 0.85

Three consecutive arginines are important for the mycobacterial peptide deformylase enzyme activity. J Biol Chem (2008) 0.81

High-affinity RNA Aptamers Against the HIV-1 Protease Inhibit Both In Vitro Protease Activity and Late Events of Viral Replication. Mol Ther Nucleic Acids (2015) 0.76

Elucidating the druggable interface of protein-protein interactions using fragment docking and coevolutionary analysis. Proc Natl Acad Sci U S A (2016) 0.76

HIV-1 protease function and structure studies with the simplicial neighborhood analysis of protein packing method. Proteins (2008) 0.75

Towards the control of intracellular protein turnover: mitochondrial Lon protease inhibitors versus proteasome inhibitors. Biochimie (2007) 1.06

HIV-1 protease and reverse transcriptase control the architecture of their nucleocapsid partner. PLoS One (2007) 0.97

Disruption of the HIV-1 protease dimer with interface peptides: structural studies using NMR spectroscopy combined with [2-(13)C]-Trp selective labeling. Biopolymers (2007) 0.91

Mutational analysis of the CG recognizing DNA methyltransferase SssI: insight into enzyme-DNA interactions. Biochim Biophys Acta (2009) 0.90

Coumarinic derivatives show anti-inflammatory effects on alveolar macrophages, but their anti-elastase activity is essential to reduce lung inflammation in vivo. Int Immunopharmacol (2008) 0.90

Novel fluorinated pseudopeptides as proteasome inhibitors. Bioorg Med Chem Lett (2008) 0.87

Dimer disruption and monomer sequestration by alkyl tripeptides are successful strategies for inhibiting wild-type and multidrug-resistant mutated HIV-1 proteases. Biochemistry (2009) 0.85

Metal-organic compounds: a new approach for drug discovery. N1-(4-methyl-2-pyridyl)-2,3,6-trimethoxybenzamide copper(II) complex as an inhibitor of human immunodeficiency virus 1 protease. Biochem Pharmacol (2002) 0.84

Molecular tongs containing amino acid mimetic fragments: new inhibitors of wild-type and mutated HIV-1 protease dimerization. J Med Chem (2006) 0.84

Regulation of the 26S proteasome activities by peptides mimicking cleavage products. Biochem Biophys Res Commun (2002) 0.83

Novel organic proteasome inhibitors identified by virtual and in vitro screening. J Med Chem (2010) 0.83

20S proteasome inhibition: designing noncovalent linear peptide mimics of the natural product TMC-95A. ChemMedChem (2010) 0.81

1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases. Bioorg Med Chem Lett (2013) 0.81

Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome. J Med Chem (2013) 0.81

α- and β-hydrazino acid-based pseudopeptides inhibit the chymotrypsin-like activity of the eukaryotic 20S proteasome. Eur J Med Chem (2013) 0.80

Linear TMC-95-based proteasome inhibitors. J Med Chem (2007) 0.80

Thyroxine-derivatives of lipopeptides: bifunctional dimerization inhibitors of human immunodeficiency virus-1 protease. Biochem Pharmacol (2003) 0.78

Toward the first nonpeptidic molecular tong inhibitor of wild-type and mutated HIV-1 protease dimerization. ChemMedChem (2010) 0.78

Noncovalent inhibition of 20S proteasome by pegylated dimerized inhibitors. Eur J Med Chem (2012) 0.78

Development of lipopeptides for inhibiting 20S proteasomes. Bioorg Med Chem Lett (2006) 0.78

Dimerization inhibitors of HIV-1 protease based on a bicyclic guanidinium subunit. J Med Chem (2003) 0.78

Toward the first class of suicide inhibitors of kallikreins involved in skin diseases. J Med Chem (2014) 0.77

New constrained "molecular tongs" designed to dissociate HIV-1 protease dimer. J Med Chem (2004) 0.77

Carbonylhydrazide-based molecular tongs inhibit wild-type and mutated HIV-1 protease dimerization. J Med Chem (2012) 0.76

Noncovalent fluorescent probes of human immuno- and constitutive proteasomes. J Med Chem (2014) 0.76

[Proteasome and proteolysis]. J Soc Biol (2004) 0.75

AZT and AZT-monophosphate prodrugs incorporating HIV-protease substrate fragment: synthesis and evaluation as specific drug delivery systems. Antivir Chem Chemother (2006) 0.75

Liberation of an N-terminal proline-rich peptide from the cryptic proteinase of fibronectin by auto-proteolysis. Arch Biochem Biophys (2008) 0.75

Proteasome inhibitors. Prog Mol Subcell Biol (2002) 0.75

Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins. Eur J Med Chem (2013) 0.75

A new series of N5 derivatives of the 1,1,5-trimethyl furo[3,4-c]pyridine-3,4-dione (cerpegin) selectively inhibits the post-acid activity of mammalian 20S proteasomes. Bioorg Med Chem Lett (2012) 0.75

C1 and N5 derivatives of cerpegin: synthesis of a new series based on structure-activity relationships to optimize their inhibitory effect on 20S proteasome. Bioorg Med Chem Lett (2013) 0.75